EASL临床实践指南:药物性肝损伤
EASL发布药物性肝损伤临床实践指南,针对特异质性(不可预测)药物性肝损伤,因涉及药物、草药及膳食补充剂众多,临床表现和病理表型多样且缺乏特异性生物标志物,诊断需高度警惕并仔细排除其他肝病病因;指南汇总了危险因素、诊断、管理和风险最小化策略的现有证据。
要点
- 特异质性药物性肝损伤诊断需高度警惕并仔细排除其他肝病病因。
- 特异质性药物性肝损伤可导致严重的急性肝衰竭,目前尚无有效疗法。
- 指南汇总危险因素、诊断、管理和风险最小化策略的证据。
核心结论
- 特异质性药物性肝损伤可表现为多种临床和病理表型,诊断需高度警惕并仔细排除其他肝病病因。
- 特异质性药物性肝损伤可导致特别严重的急性肝衰竭,目前尚无有效疗法。
研究设计与样本
- EASL临床实践指南,总结关于药物性肝损伤危险因素、诊断、管理和风险最小化策略的现有证据。
局限性
- 原文指出目前缺乏特异性生物标志物,诊断过程存在不确定性。
- 原文指出特异质性药物性肝损伤导致的急性肝衰竭尚无有效疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
引用
- EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019. PMID: 30926241. doi:10.1016/j.jhep.2019.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。